PharmaShots Weekly Snapshot (March 25-29, 2019)


Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene Therapies for Neurological Disorders

Published: March 29, 2019 | Tags: Takeda, Signs, Multi- Target Agreement, StrideBio, Develop, Gene Therapies, Neurological Diseases

Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH) for ALS Biomarker Study

Published: March 29, 2019 | Tags: Mitsubishi Tanabe Pharma, MTPA, Collaborates, Massachusetts General Hospital, MGH, ALS Biomarker Study

AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi Sankyo for $6.9B

Published: March 29, 2019 | Tags: AstraZeneca, Signs, WW, Collaboration, Daiichi Sankyo, $6.9B

Gilead and Galapagos’ Report Results of Filgotinib in P-III FINCH 3 Trial for Moderate-To-Severe Active Rheumatoid Arthritis (RA)

Published: March 29, 2019 | Tags: Gilead, Galapagos, Report, Results, Filgotinib, P-III, FINCH 3 Trial, Moderate-To-Severe, Active, Rheumatoid Arthritis, RA

Bayer Signs a Non-Exclusive Licensing Agreement with ProteoNic Biotechnology for its 2G UNic Technology

Published: March 29, 2019 | Tags: Bayer, Signs, Non-Exclusive Licensing Agreement, ProteoNic Biotechnology, 2G UNic Technology 

Johnson & Johnson (J&J) Vision Launches Acuvue Oasys with Transitions Light Intelligent Technology in the US

Published: March 28, 2019 | Tags: Johnson N Johnson Vision, Launches, Acuvue Oasys, Transitions Light Intelligent Technology, US

apple ecg

Apple Launches its Watch Series 4 Enabled with ECG App and Irregular Rhythm Notification in Europe and Hong Kong

Published: March 28, 2019 | Tags: Apple, Launches, Watch Series 4, ECG App, Irregular Rhythm Notification, Europe, Hong Kong

Ono Pharmaceutical Signs a Multi-Year Collaboration with LifeArc and Cancer Research UK to Develop Immuno-Therapies for Cancer

Published: March 28, 2019 | Tags: Ono Pharmaceutical, Signs, Multi-Year, Collaboration, LifeArc, Cancer Research UK, Develop, Immuno-Therapies, Cancer

Chugai’s Risdiplam Receives MHLW’s Orphan Drug Designation for Spinal Muscular Atrophy (SMA)

Published: March 28, 2019 | Tags: Chugai, Risdiplam, Receives, MHLW, Orphan Drug Designation, Spinal Muscular Atrophy

BioLineRx Reports Engraftment Data of BL-8040 in P-III GENESIS Trial for Patients with Multiple Myeloma

Published: March 28, 2019 | Tags: BioLineRx, Reports, Engraftment Data, BL-8040, P-III, GENESIS Trial, Patients, Multiple Myeloma

Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

Published: March 27, 2019 | Tags: Jazz Pharmaceuticals, Reports, Results, ZP-258, P-III, Study, Narcolepsy Patients, Cataplexy, ExcessiveDaytime Sleepiness

Gilead’s Biktarvy (Bictegravir, Emtricitabine and Tenofovir Alafenamide) Receives MHLW’s Approval for HIV-1 Infection in Japan

Published: March 27, 2019 | Tags: Gilead, Biktarvy, Bictegravir, Emtricitabine,Tenofovir Alafenamide, Receives, Japan, Ministry of Health, Labour and Welfare, Approval, HIV-1 Infection

AstraZeneca’s Forxiga (dapagliflozin) Receives MHLW’s Approval for Type-1 Diabetes (T1D) in Japan

Published: March 27, 2019 | Tags: AstraZeneca, Forxiga, dapagliflozin, Receives, MHLW ,Approval, Type-1 Diabetes, T1D,  Adults

Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext to Develop Therapies for Autoimmune Disorders

Published: March 27, 2019 | Tags: Lilly, Signs, Research Collaboration, ImmuNext, Develop, Commercialize, Novel Therapies, Autoimmune Diseases

Novartis’ Mayzent (siponimod) Receives FDA’s Approval for Patients with Secondary Progressive Multiple Sclerosis (SPMS)

Published: March 27, 2019 | Tags: Novartis, Mayzent, siponimod, Receives, FDA, Approval, Patients, Secondary Progressive Multiple Sclerosis, SPMS

Celgene Files NDA for Ozanimod to the US FDA for Relapsing Forms of Multiple Sclerosis (RMS)

Published: March 26, 2019 | Tags: Celgene, Submits, Application, FDA, Ozanimod, Treatment, Relapsing Multiple Sclerosis

AbbVie’s Skyrizi (risankizumab) Receives Japanese Ministry of Health, Labour and Welfare (MHLW) Approval to Treat Plaque Psoriasis, Generalized Pustular Psoriasis, Erythrodermic Psoriasis and Psoriatic Arthritis in Adults

Published: March 26, 2019 | Tags: AbbVie, Skyrizi, risankizumab, Receives, FDA, Approval, Treat, Plaque Psoriasis, Generalized Pustular Psoriasis, Erythrodermic Psoriasis, Psoriatic Arthritis, Adults

Almirall Signs a Research Collaboration with HitGen for its DNA-Encoded Technology

Published: March 26, 2019 | Tags: Almirall, Signs, Research Collaboration, HitGen, Technology

lupin1

Lupin and YL Biologics’ Etanercept Biosimilar (YLB113) Receive PMDA’s Approval for Moderate-to-Severe Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA) in Japan

Published: March 26, 2019 | Tags: Lupin, YL Biologics, Etanercept, YLB113, Receive, PMDA, Approval, Moderate to Severe, Rheumatoid Arthritis, RA, Juvenile Idiopathic Arthritis, JIA, Japan

AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin for its Fasenra (beralizumab)

Published: March 26, 2019 | Tags: AstraZeneca, Signs, Development, Commercialization, Agreements, Kyowa Hakko Kirin, Fasenra, beralizumab

Thermo Fischer to Acquire Brammer Bio for $1.7B

Published: March 25, 2019 | Tags: Thermo Fischer; Acquire; Brammer Bio; $1.7B

AstraZeneca’s Forxiga (dapagliflozin) Receives EU’s Approval for Type-1 Diabetes (T1D) in Adults

Published: March 25, 2019 | Tags: AstraZeneca, Forxiga, dapagliflozin, Receives, EU, Approval, Type-1 Diabetes, T1D, Adults

Eisai Signs a Research Agreement with Cerveau Technologies for its Novel Tau Imaging Agent

Published: March 25, 2019 | Tags: Eisai, Signs, Research Agreement, Cerveau Technologies, Novel Tau Imaging Agent

Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates in Immuno-Oncology

Published: March 25, 2019 | Tags: Takeda, Collaborates, LegoChem Biosciences, LCB, Develop, Antibody-Drug Conjugates, Immuno-Oncology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post